We have a lot of experience with this kind of business model and anticipate equal success in the psoriasis marketplace as we have achieved in the neurology marketplace. Mr. Mullen also said that Biogen is uniquely positioned to capitalize on the new technologies coming out of the human genome project. Now that so much information is available about the human genome, we believe that companies like Biogen, with our extraordinary depth of experience and understanding of biology, will be able to use a 'pull' or biomining strategy to identify selective genes and apply our knowledge of biological systems to enhanced target identification and drug development. These side effects usually go away within a day after the injection and occur less often as the treatment continues. Factors which could cause actual results to differ materially from the Company's current expectations include the risk that the Company will encounter one or more technical hurdles associated with new drug development or that problems or delays may arise during preparations for or the conduct of clinical trials, or that results of clinical trials may be different than those seen in earlier stage or smaller trials or in preclinical work as well as the other risks and uncertainties associated with drug development and commercialization described in the Company's periodic reports filed with the Securities and Exchange Commission.
Drug development involves a high degree of risk.
Success in early stage clinical trials or preclinical work does not ensure that later stage or larger scale clinical trials will be successful. Biogen, Inc., winner of the U.S. National Medal of Technology, is a biopharmaceutical company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. Biogen's research and development activities are focused on novel products to treat inflammatory and autoimmune diseases, neurological diseases, cancer, fibrosis and congestive heart failure. The Company maintains active clinical research programs in protein therapeutics, small molecules, genomics and gene therapy.